SoFi CEO enters prepaid forward contract on 1.5 million shares
BOSTON—Leo Chandra P., a director at Monte Rosa Therapeutics , Inc. (NASDAQ:GLUE), recently made a significant purchase of the company’s stock. According to a recent SEC filing, Chandra acquired 10,000 shares of common stock on March 24, 2025, at a price of $5.8383 per share. This transaction amounted to a total investment of $58,383. Following this transaction, Chandra’s direct ownership of the company’s stock stands at 10,000 shares. The purchase comes as the stock has declined nearly 15% over the past week, with analysts setting price targets ranging from $10 to $20 per share. According to InvestingPro analysis, the stock appears undervalued at current levels.
Monte Rosa Therapeutics, based in Boston, specializes in developing novel therapies in the field of life sciences. The company’s stock is traded on the NASDAQ under the ticker symbol GLUE. The company maintains a strong financial position with more cash than debt on its balance sheet and a healthy current ratio of 2.4. InvestingPro subscribers can access 8 additional key insights and a comprehensive Pro Research Report, part of the platform’s coverage of over 1,400 US stocks.
In other recent news, Monte Rosa Therapeutics reported fourth-quarter revenue of $60.64 million, significantly exceeding analyst expectations of $51.19 million. This strong performance marks the company’s first quarter of substantial revenue generation, primarily from collaboration agreements with Roche and Novartis (SIX:NOVN). Monte Rosa also reported a net income of $13.4 million for the quarter, a notable improvement from the net loss of $33.3 million in the same period last year. The company’s financial position was further strengthened by a $150 million upfront payment from its licensing agreement with Novartis for VAV1 molecular glue degraders, including MRT-6160. Additionally, Monte Rosa provided updates on its clinical programs, highlighting encouraging early signals from its MRT-2359 study in castration-resistant prostate cancer patients. Positive results from the Phase 1 study of MRT-6160 were also reported, showing deep VAV1 degradation and a favorable safety profile, supporting advancement into Phase 2 studies. Monte Rosa ended the quarter with $377 million in cash and equivalents, which it expects will fund operations into 2028.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.